Low thymic activity and dendritic cell numbers are associated with the immune response to primary viral infection in elderly humans

Journal of Immunology

Volumn 195, Issue 10, 2015, Pages 4699-4711

  Schulz, Axel Ronald ^a   Mälzer, Julia Nora ^a   Domingo, Cristina ^b   Jürchott, Karsten ^a   Grützkau, Andreas ^a   Babel, Nina ^a   Nienen, Mikalai ^a   Jelinek, Tomas ^c   Niedrig, Matthias ^b   Thiel, Andreas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

^c Berlin Center for Travel and Tropical Medicine   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; YELLOW FEVER VACCINE; IMMUNOGLOBULIN G; LIVE VACCINE; VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; EX VIVO STUDY; EXPERIMENTAL INFECTION; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; THYMUS; VIRUS IMMUNITY; YELLOW FEVER; AGE; AGING; BLOOD; CELL COUNT; CYTOLOGY; IMMUNOCOMPETENCE; IMMUNOLOGY; LYMPHOCYTE COUNT; MIDDLE AGED; PHYSIOLOGY; VACCINATION; VIREMIA; YELLOW FEVER VIRUS; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; AGING; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL COUNT; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOCOMPETENCE; IMMUNOGLOBULIN G; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; THYMUS GLAND; VACCINATION; VACCINES, ATTENUATED; VIREMIA; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS; YOUNG ADULT;

EID: 84958593673     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1500598     Document Type: Article

References (74)

1. Fulop, T., A. Larbi, R. Kotb, F. de Angelis, and G. Pawelec. 2011. Aging, immunity, and cancer. Discov. Med. 11: 537-550.
2. Goronzy, J. J., and C. M. Weyand. 2012. Immune aging and autoimmunity. Cell. Mol. Life Sci. 69: 1615-1623.
3. Gavazzi, G., and K. H. Krause. 2002. Ageing and infection. Lancet Infect. Dis. 2: 659-666.
4. Maue, A. C., E. J. Yager, S. L. Swain, D. L. Woodland, M. A. Blackman, and L. Haynes. 2009. T-cell immunosenescence: lessons learned from mouse models of aging. Trends Immunol. 30: 301-305.
5. Wertheimer, A. M., J. L. Uhrlaub, A. Hirsch, G. Medigeshi, J. Sprague, A. Legasse, J. Wilk, C. A. Wiley, P. Didier, R. B. Tesh, et al. 2010. Immune response to the West Nile virus in aged non-human primates. PLoS One 5: e15514.
6. Goronzy, J. J., and C. M. Weyand. 2013. Understanding immunosenescence to improve responses to vaccines. Nat. Immunol. 14: 428-436.
7. Vallejo, A. N. 2011. Immunological hurdles of ageing: indispensable research of the human model. Ageing Res. Rev. 10: 315-318.
8. Brunner, S., D. Herndler-Brandstetter, B. Weinberger, and B. Grubeck-Loebenstein. 2011. Persistent viral infections and immune aging. Ageing Res. Rev. 10: 362-369.
9. Weinberger, B., and B. Grubeck-Loebenstein. 2012. Vaccines for the elderly. Clin. Microbiol. Infect. 18(Suppl. 5): 100-108. doi:10.1111/j.1469-0691.2012.03944.x
10. Hainz, U., B. Jenewein, E. Asch, K. P. Pfeiffer, P. Berger, and B. Grubeck-Loebenstein. 2005. Insufficient protection for healthy elderly adults by tetanus and TBE vaccines. Vaccine 23: 3232-3235.
11. Blackman, M. A., and D. L. Woodland. 2011. The narrowing of the CD8 T cell repertoire in old age. Curr. Opin. Immunol. 23: 537-542.
12. Cicin-Sain, L., S. Smyk-Pearson, N. Currier, L. Byrd, C. Koudelka, T. Robinson, G. Swarbrick, S. Tackitt, A. Legasse, M. Fischer, et al. 2010. Loss of naive T cells and repertoire constriction predict poor response to vaccination in old primates. J. Immunol. 184: 6739-6745.
13. Yager, E. J., M. Ahmed, K. Lanzer, T. D. Randall, D. L. Woodland, and M. A. Blackman. 2008. Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus. J. Exp. Med. 205: 711-723.
14. Shaw, A. C., D. R. Goldstein, and R. R. Montgomery. 2013. Age-dependent dysregulation of innate immunity. Nat. Rev. Immunol. 13: 875-887.
15. Kohler, S., N. Bethke, M. Böthe, S. Sommerick, M. Frentsch, C. Romagnani, M. Niedrig, and A. Thiel. 2012. The early cellular signatures of protective immunity induced by live viral vaccination. Eur. J. Immunol. 42: 2363-2373.
16. Ahmed, R., and R. S. Akondy. 2011. Insights into human CD8(+) T-cell memory using the yellow fever and smallpox vaccines. Immunol. Cell Biol. 89: 340-345.
17. Liprandi, F., and R. Walder. 1983. Replication of virulent and attenuated strains of yellow fever virus in human monocytes and macrophage-like cells (U937). Arch. Virol. 76: 51-61.
18. Gaucher, D., R. Therrien, N. Kettaf, B. R. Angermann, G. Boucher, A. Filali-Mouhim, J. M. Moser, R. S. Mehta, D. R. Drake, III, E. Castro, et al. 2008. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J. Exp. Med. 205: 3119-3131.
19. Poland, J. D., C. H. Calisher, T. P. Monath, W. G. Downs, and K. Murphy. 1981. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull. World Health Organ. 59: 895-900.
20. Monath, T. P. 2012. Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev. Vaccines 11: 427-448.
21. Barwick Eidex, R., Yellow Fever Vaccine Safety Working Group. 2004. History of thymoma and yellow fever vaccination. Lancet 364: 936.
22. Khromava, A. Y., R. B. Eidex, L. H. Weld, K. S. Kohl, R. D. Bradshaw, R. T. Chen, and M. S. Cetron, Yellow Fever Vaccine Safety Working Group. 2005. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 23: 3256-3263.
23. Domingo, C., P. Patel, J. Yillah, M. Weidmann, J. A. Méndez, E. R. Nakouné, and M. Niedrig. 2012. Advanced yellow fever virus genome detection in pointof-care facilities and reference laboratories. J. Clin. Microbiol. 50: 4054-4060.
24. Reinhardt, B., R. Jaspert, M. Niedrig, C. Kostner, and J. L'age-Stehr. 1998. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J. Med. Virol. 56: 159-167.
25. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27: 493-497.
26. Miller, J. D., R. G. van der Most, R. S. Akondy, J. T. Glidewell, S. Albott, D. Masopust, K. Murali-Krishna, P. L. Mahar, S. Edupuganti, S. Lalor, et al. 2008. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28: 710-722.
27. Akondy, R. S., N. D. Monson, J. D. Miller, S. Edupuganti, D. Teuwen, H. Wu, F. Quyyumi, S. Garg, J. D. Altman, C. Del Rio, et al. 2009. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J. Immunol. 183: 7919-7930.
28. Akondy, R. S., P. L. Johnson, H. I. Nakaya, S. Edupuganti, M. J. Mulligan, B. Lawson, J. D. Miller, B. Pulendran, R. Antia, and R. Ahmed. 2015. Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination. Proc. Natl. Acad. Sci. USA 112: 3050-3055.
29. Blom, K., M. Braun, M. A. Ivarsson, V. D. Gonzalez, K. Falconer, M. Moll, H. G. Ljunggren, J. Michaëlsson, and J. K. Sandberg. 2013. Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector- to a memory-type response. J. Immunol. 190: 2150-2158.
30. Roederer, M., J. L. Nozzi, and M. C. Nason. 2011. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 79: 167-174.
31. R-Core-Team. 2012. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
32. Zaunders, J. J., W. B. Dyer, M. L. Munier, S. Ip, J. Liu, E. Amyes, W. Rawlinson, R. De Rose, S. J. Kent, J. S. Sullivan, et al. 2006. CD127+CCR5+CD38+++ CD4+ Th1 effector cells are an early component of the primary immune response to vaccinia virus and precede development of interleukin-2+ memory CD4+ T cells. J. Virol. 80: 10151-10161.
33. Fagnoni, F. F., R. Vescovini, G. Passeri, G. Bologna, M. Pedrazzoni, G. Lavagetto, A. Casti, C. Franceschi, M. Passeri, and P. Sansoni. 2000. Shortage of circulating naive CD8(+) T cells provides new insights on immunodeficiency in aging. Blood 95: 2860-2868.
34. Appay, V., and D. Sauce. 2014. Naive T cells: the crux of cellular immune aging? Exp. Gerontol. 54: 90-93.
35. Bassi, M. R., M. Kongsgaard, M. A. Steffensen, C. Fenger, M. Rasmussen, K. Skjdt, B. Finsen, A. Stryhn, S. Buus, J. P. Christensen, and A. R. Thomsen. 2015. CD8+ T cells complement antibodies in protecting against yellow fever virus. J. Immunol. 194: 1141-1153.
36. Seder, R. A., P. A. Darrah, and M. Roederer. 2008. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8: 247-258.
37. Boyd, A., J. R. Almeida, P. A. Darrah, D. Sauce, R. A. Seder, V. Appay, G. Gorochov, and M. Larsen. 2015. Pathogen-Specific T Cell Polyfunctionality Is a Correlate of T Cell Efficacy and Immune Protection. [Published erratum appears in 2015 PLoS ONE. 10: e0138395.] PLoS One 10: e0128714.
38. Darrah, P. A., D. T. Patel, P. M. De Luca, R.W. Lindsay, D. F. Davey, B. J. Flynn, S. T. Hoff, P. Andersen, S. G. Reed, S. L. Morris, et al. 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13: 843-850.
39. Kannanganat, S., C. Ibegbu, L. Chennareddi, H. L. Robinson, and R. R. Amara. 2007. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J. Virol. 81: 8468-8476.
40. Kimmig, S., G. K. Przybylski, C. A. Schmidt, K. Laurisch, B. Möwes, A. Radbruch, and A. Thiel. 2002. Two subsets of naive T helper cells with distinct T cell receptor excision circle content in human adult peripheral blood. J. Exp. Med. 195: 789-794.
41. Kohler, S., U. Wagner, M. Pierer, S. Kimmig, B. Oppmann, B. Möwes, K. Jülke, C. Romagnani, and A. Thiel. 2005. Post-thymic in vivo proliferation of naive CD4+ T cells constrains the TCR repertoire in healthy human adults. Eur. J. Immunol. 35: 1987-1994.
42. Querec, T. D., R. S. Akondy, E. K. Lee,W. Cao, H. I. Nakaya, D. Teuwen, A. Pirani, K. Gernert, J. Deng, B. Marzolf, et al. 2009. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10: 116-125.
43. Muyanja, E., A. Ssemaganda, P. Ngauv, R. Cubas, H. Perrin, D. Srinivasan, G. Canderan, B. Lawson, J. Kopycinski, A. S. Graham, et al. 2014. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine. J. Clin. Invest. 124: 3147-3158.
44. Trzonkowski, P., J. Mysliwska, E. Szmit, J. Wieckiewicz, K. Lukaszuk, L. B. Brydak, M. Machała, and A. Mysliwski. 2003. Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination-an impact of immunosenescence. Vaccine 21: 3826-3836.
45. Derhovanessian, E., H. Theeten, K. Hähnel, P. Van Damme, N. Cools, and G. Pawelec. 2013. Cytomegalovirus-associated accumulation of latedifferentiated CD4 T-cells correlates with poor humoral response to influenza vaccination. Vaccine 31: 685-690.
46. Fülöp, T., A. Larbi, and G. Pawelec. 2013. Human T cell aging and the impact of persistent viral infections. Front. Immunol. 4: 271.
47. Roukens, A. H., D. Soonawala, S. A. Joosten, A.W. de Visser, X. Jiang, K. Dirksen, M. de Gruijter, J. T. van Dissel, P. J. Bredenbeek, and L. G. Visser. 2011. Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study. PLoS One 6: e27753.
48. Pulendran, B., J. Miller, T. D. Querec, R. Akondy, N. Moseley, O. Laur, J. Glidewell, N. Monson, T. Zhu, H. Zhu, et al. 2008. Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J. Infect. Dis. 198: 500-507.
49. Po, J. L., E. M. Gardner, F. Anaraki, P. D. Katsikis, and D. M. Murasko. 2002. Age-associated decrease in virus-specific CD8+ T lymphocytes during primary influenza infection. Mech. Ageing Dev. 123: 1167-1181.
50. Monath, T. P., F. Guirakhoo, R. Nichols, S. Yoksan, R. Schrader, C. Murphy, P. Blum, S. Woodward, K. McCarthy, D. Mathis, et al. 2003. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J. Infect. Dis. 188: 1213-1230.
51. Nikolich-Zugich, J., G. Li, J. L. Uhrlaub, K. R. Renkema, and M. J. Smithey. 2012. Age-related changes in CD8 T cell homeostasis and immunity to infection. Semin. Immunol. 24: 356-364.
52. Murasko, D. M., and J. Jiang. 2005. Response of aged mice to primary virus infections. Immunol. Rev. 205: 285-296.
53. Brien, J. D., J. L. Uhrlaub, A. Hirsch, C. A. Wiley, and J. Nikolich-Zugich. 2009. Key role of T cell defects in age-related vulnerability to West Nile virus. J. Exp. Med. 206: 2735-2745.
54. Smithey, M. J., K. R. Renkema, B. D. Rudd, and J. Nikolich-Zugich. 2011. Increased apoptosis, curtailed expansion and incomplete differentiation of CD8+ T cells combine to decrease clearance of L. monocytogenes in old mice. Eur. J. Immunol. 41: 1352-1364.
55. Parsons, R., A. Lelic, L. Hayes, A. Carter, L. Marshall, C. Evelegh, M. Drebot, M. Andonova, C. McMurtrey, W. Hildebrand, et al. 2008. The memory T cell response to West Nile virus in symptomatic humans following natural infection is not influenced by age and is dominated by a restricted set of CD8+ T cell epitopes. J. Immunol. 181: 1563-1572.
56. Piazza, P., C. P. McMurtrey, A. Lelic, R. L. Cook, R. Hess, E. Yablonsky, L. Borowski, M. B. Loeb, J. L. Bramson, W. H. Hildebrand, and C. R. Rinaldo. 2010. Surface phenotype and functionality of WNV specific T cells differ with age and disease severity. PLoS One 5: e15343.
57. Lelic, A., C. P. Verschoor, M. Ventresca, R. Parsons, C. Evelegh, D. Bowdish, M. R. Betts, M. B. Loeb, and J. L. Bramson. 2012. The polyfunctionality of human memory CD8+ T cells elicited by acute and chronic virus infections is not influenced by age. PLoS Pathog. 8: e1003076.
58. Lanzer, K. G., L. L. Johnson, D. L. Woodland, and M. A. Blackman. 2014. Impact of ageing on the response and repertoire of influenza virus-specific CD4 T cells. Immun. Ageing 11: 9.
59. Pérez-Cabezas, B., M. Naranjo-Gómez, M. A. Fernández, J. R. Grífols, R. Pujol-Borrell, and F. E. Borràs. 2007. Reduced numbers of plasmacytoid dendritic cells in aged blood donors. Exp. Gerontol. 42: 1033-1038.
60. Garbe, K., K. Bratke, S. Wagner, J. C. Virchow, and M. Lommatzsch. 2012. Plasmacytoid dendritic cells and their Toll-like receptor 9 expression selectively decrease with age. Hum. Immunol. 73: 493-497.
61. Seidler, S., H. W. Zimmermann, M. Bartneck, C. Trautwein, and F. Tacke. 2010. Age-dependent alterations of monocyte subsets and monocyte-related chemokine pathways in healthy adults. BMC Immunol. 11: 30.
62. Monath, T. P., M. S. Cetron, K. McCarthy, R. Nichols, W. T. Archambault, L. Weld, and P. Bedford. 2005. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum. Vaccin. 1: 207-214.
63. Monath, T. P., R. Nichols, W. T. Archambault, L. Moore, R. Marchesani, J. Tian, R. E. Shope, N. Thomas, R. Schrader, D. Furby, and P. Bedford. 2002. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am. J. Trop. Med. Hyg. 66: 533-541.
64. Hacker, U. T., T. Jelinek, S. Erhardt, A. Eigler, G. Hartmann, H. D. Nothdurft, and S. Endres. 1998. In vivo synthesis of tumor necrosis factor-alpha in healthy humans after live yellow fever vaccination. J. Infect. Dis. 177: 774-778.
65. Bruni, D., M. Chazal, L. Sinigaglia, L. Chauveau, O. Schwartz, P. Desprès, and N. Jouvenet. 2015. Viral entry route determines how human plasmacytoid dendritic cells produce type I interferons. Sci. Signal. 8: ra25.
66. Solana, R., R. Tarazona, I. Gayoso, O. Lesur, G. Dupuis, and T. Fulop. 2012. Innate immunosenescence: effect of aging on cells and receptors of the innate immune system in humans. Semin. Immunol. 24: 331-341.
67. Agrawal, A., and S. Gupta. 2011. Impact of aging on dendritic cell functions in humans. Ageing Res. Rev. 10: 336-345.
68. Qian, F., X. Wang, L. Zhang, A. Lin, H. Zhao, E. Fikrig, and R. R. Montgomery. 2011. Impaired interferon signaling in dendritic cells from older donors infected in vitro with West Nile virus. J. Infect. Dis. 203: 1415-1424.
69. Smithey, M. J., G. Li, V. Venturi, M. P. Davenport, and J. Nikolich-Zugich. 2012. Lifelong persistent viral infection alters the naive T cell pool, impairing CD8 T cell immunity in late life. J. Immunol. 189: 5356-5366.
70. Cicin-Sain, L., J. D. Brien, J. L. Uhrlaub, A. Drabig, T. F. Marandu, and J. Nikolich-Zugich. 2012. Cytomegalovirus infection impairs immune responses and accentuates T-cell pool changes observed in mice with aging. PLoS Pathog. 8: e1002849.
71. Who. 2015. Vaccines and vaccination against yellow fever: WHO Position Paper, June 2013-recommendations. Vaccine 33: 76-77.
72. Jean, C. M., S. Honarmand, J. K. Louie, and C. A. Glaser. 2007. Risk factors for West Nile virus neuroinvasive disease, California, 2005. Emerg. Infect. Dis. 13: 1918-1920.
73. Peiris, J. S., C. M. Chu, V. C. Cheng, K. S. Chan, I. F. Hung, L. L. Poon, K. I. Law, B. S. Tang, T. Y. Hon, C. S. Chan, et al; HKU/UCH SARS Study Group. 2003. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361: 1767-1772.
74. Liniger, M., A. Zuniga, and H. Y. Naim. 2007. Use of viral vectors for the development of vaccines. Expert Rev. Vaccines 6: 255-266.